Apyx Medical Corporation
NASDAQTotal Valuation
Apyx Medical Corporation carries a market capitalization of 128.86M, placing it among publicly traded companies globally. Its enterprise value stands at 201.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 128.86M |
| Enterprise Value | 201.54M |
Share Statistics
Apyx Medical Corporation currently has 42.12M shares outstanding.
| Shares Outstanding | 42.12M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3.23, and the price-to-book ratio stands at 17.73.
| PE Ratio | N/A |
| PS Ratio | 3.23 |
| PB Ratio | 17.73 |
| P/TBV Ratio | 17.73 |
| P/FCF Ratio | -20.46 |
| P/OCF Ratio | -18.60 |
Enterprise Valuation
| EV / Sales | 3.45 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Apyx Medical Corporation maintains a current ratio of 5.68, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 357.35, indicating elevated leverage, while an interest coverage ratio of -0.49 demonstrates limited ability to service its debt obligations.
| Current Ratio | 5.68 |
| Quick Ratio | 4.41 |
| Debt / Equity | 357.35 |
| Debt / EBITDA | -14.38 |
| Interest Coverage | -0.49 |
Financial Efficiency
| Return on Equity (ROE) | -96.38 |
| Return on Assets (ROA) | -14.48 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.25 |
Taxes
| Income Tax | 439,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Apyx Medical Corporation's stock has gained approximately 51.48515% over the past 52 weeks. The 50-day moving average sits at 3.50, while the 200-day moving average is 3.77.
| Beta (5Y) | N/A |
| 52-Week Price Change | 51.48515% |
| 50-Day Moving Average | 3.50 |
| 200-Day Moving Average | 3.77 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Apyx Medical Corporation generated 58.42M in revenue and converted that into -8.63M in net income, yielding earnings per share of -0.20. EBITDA reached -2.75M, while operating income came in at -3.54M.
| Revenue | 58.42M |
| Gross Profit | 37.09M |
| Operating Income | -3.54M |
| Pretax Income | -7.97M |
| Net Income | -8.63M |
| EBITDA | -2.75M |
| EBIT | -3.54M |
| Earnings Per Share (EPS) | -0.20 |
Balance Sheet
Apyx Medical Corporation holds 27.62M in cash and equivalents against 39.63M in total debt, resulting in a net debt position of 7.71M. Total book value stands at 10.66M, with working capital of 43.80M providing operational flexibility.
| Cash & Cash Equivalents | 27.62M |
| Total Debt | 39.63M |
| Net Debt | 7.71M |
| Equity (Book Value) | 10.66M |
| Book Value Per Share | 0.25 |
| Working Capital | 43.80M |
Cash Flow
Apyx Medical Corporation produced -10.13M in operating cash flow over the past twelve months. After subtracting -920,000.00 in capital expenditures, free cash flow totaled -11.05M - equivalent to -0.26 per share.
| Operating Cash Flow | -10.13M |
| Capital Expenditures | -920,000.00 |
| Free Cash Flow | -11.05M |
| FCF Per Share | -0.26 |
Margins
Apyx Medical Corporation operates with a gross margin of 63.50, reflecting its pricing power and cost economics. The operating margin of -6.06 and net profit margin of -14.78 provide insight into operational efficiency.
| Gross Margin | 63.50 |
| Operating Margin | -6.06 |
| Pretax Margin | -13.65 |
| Profit Margin | -14.78 |
| EBITDA Margin | -4.72 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5.08 |
| FCF Yield | -4.89 |
Scores
Apyx Medical Corporation posts an Altman Z-Score of 1.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.73 |